VAXXITEK^® HVT+IBD+ILT
The Power to Protect

Protection against infectious laryngotracheitis (ILT) powered by VAXXITEK^®.

VAXXITEK^® HVT+IBD+ILT
The Power to Protect Uniquely and Conveniently

Protects against ILT, Marek’s disease (MD), and infectious bursal disease (IBD) in a single vaccination.¹

3-in 1 Protection

Protects against ILT, Marek’s disease (MD), and infectious bursal disease (IBD) in a single vaccination.¹
Immune Foundation

Uses the same backbone as VAXXITEK® HVT+IBD to help you lay a strong immune foundation.^2-9
Optimal ILT Protection

Immunogenic glycoprotein D ILT insert for optimal ILT protection
Performance Benefits

Strong immune foundation enables productivity, reduces antibiotic use, and supports return on investment.^10–15

HOW IT WORKS

1-Proven HVT+IBD platform

Built on a proven HVT+IBD platform that provides efficient, broad protection against IBD classic and MD.
2-Protection against virulent ILT

Inserted into this platform is a genetic sequence coding for glycoprotein D (gD), which is proven to give clinical protection against virulent, ILT virus (ILTV).^16,17
3-Single promoter

The ILTV gD insertion site is the same as the IBD VP2 gene, allowing for the use of a single promotor. The result is consistent antigen expression for both viral genes in a field proven mechanism of protection.

Learn more

SEE VAXXITEK^® HVT+IBD+ILT IN ACTION

VAXXITEK^® HBT+IBD+ILT PRODUCT INFORMATION

Indication

Recommended for the vaccination of healthy 18- to 19-day-old chicken embryos and one-day-old chickens against standard and variant bursal disease, fowl laryngotracheitis, and Marek’s disease

Dosage

Available in 1000, 2000, 4000 dose ampules in frozen presentation

Safety Information

Do not mix with other products, except as specified on the label
In case of human exposure, contact a physician
Administer only as recommended
Use entire contents when first opened
Do not vaccinate within 21 days before slaughter
Contains amphotericin B as a fungistatic agent
Inactivate unused contents before disposal

Download PDF

References: 1. Data on file. Boehringer Ingelheim Animal Health. 2. Hoerr FJ. Clinical Aspects of immunosuppression in poultry. Avian Dis. 2010; 54:2–15. 3. Naqi S, Thompson G, Bauman B, Mohammed H. The exacerbating effect of infectious bronchitis virus infection on the infectious bursal disease virus-induced suppression of opsonization by Escherichia coli antibody in chickens. Avian Dis. 2001; 45:52–60. 4. Alonso Castro M, Merino Cabria D, Fernandez Garcia D, et al. Evaluation of the effects of vaccination with a HVT-IBD vector vaccine on bursa Fabricii, production parameters and meat properties in broilers. Abstract presented at the XVIII Congress of the World Veterinary Poultry Association; 2013: Nantes, France. 5. Devaud I, Herin JB, Trotel A, Pagot E, Voisin F. A field study in commercial layers to evaluate the effects of an HVT-IBD vector vaccine on production performances in comparison with a live IBD vaccine. Abstract presented at the XVIII Congress of the World Veterinary Poultry Association; 2013: Nantes, France. 6. Ganapathy K, Wilkins M, Forrester A, Jones RC, Lemiere S. Protection and immune responses against virulent infectious bronchitis viruses in HVT-IBD recombinant or IBD-complex vaccinated broiler chicks. Abstract presented at the First International Respiratory Disease Conference, Athens, United States of America, 2011. 7. Lemiere S, Wilkins M, Forrester A, Jones R, Ganapathy K. Protection and immune responses against virulent infectious bronchitis (IB) viruses in herpesvirus turkey-infectious bursal disease (HVT-IBD) vaccinated broiler chicks. Poster presentation. Abstract presented at the XVII Congress of the World Veterinary Poultry Association; 2011: Cancun, Mexico. 8. Rautenschlein S, Lemiere S, Prandini F. Evaluation of the effects of an HVT-IBD vector vaccine on the immune system of layer pullets in comparison with two commercial live IBD vaccines. Abstract presented at the XVIII Congress of the World Veterinary Poultry Association; 2013: Nantes, France. 9. Rautenschlein S, Lemiere S, Simon B, Prandini F. A comparison of the effects on the humoral and cell-mediated immunity between an HVT-IBD vector vaccine and an IBDV immune complex vaccine after in ovo vaccination of commercial broilers. Abstract presented at the XVIII Congress of the World Veterinary Poultry Association; 2013: Nantes, France. 10. Lemiere S, Rojo F, Fernandez R, et al. Benefits of the herpesvirus of turkey vector vaccine of infectious bursal disease in control of immune-depression in broilers and decrease of use of antibiotic medication. Abstract presented at: The XVIII Congress of the World Veterinary Poultry Association; 2013: Nantes, France. 11. Hoelzer K, Bielke L, Blake DP, et al. Vaccines as alternatives to antibiotics for food producing animals. Part 2: new approaches and potential solutions. Vet Res. 2018;49:70. 12. Atienza JC, Nagera AJ, Martinez PO, et al. Evaluation of a herpesvirus of turkey vector vaccine inducing protection against infectious bursal and Marek’s diseases (VAXXITEK® HVT+IBD) under Philippines field conditions. In: Proceedings from the XXIII World’s Poultry Congress; 29 June 29–July 4, 2008; Queensland, Australia. 13. Rautenschlein S, Lemiere S, Simon B, Prandini F. A comparison of the effects of the humoral and cell-mediated immunity between an HVT-IBD vector vaccine and an IBDV-immune complex vaccine after in ovo vaccination of commercial broilers. Abstract presented at the XVII Congress of the World Veterinary Poultry Association; 2011: Cancun, Mexico. 14. Tang SF, He SJ, Li WM, Lemiere S. Field experience of vaccination in day-old broiler chickens with a herpesvirus turkey-infectious bursal disease (HVT-IBD) vector vaccine in different systems of chicken production across China. Poster presentation. Abstract presented at the XVII Congress of the World Veterinary Poultry Association; 2011: Cancun, Mexico. 15. Zhou X, Wang D, Xiong J, Zhang P, Li Y, She R. Protection of chickens, with or without maternal antibodies, against IBDV infection by
a recombinant IBDV-VP2 protein. Vaccine. 2010;28:3990–3996. 16. Kanabagatte Basavarajappa M, Kumar S, Khattar SK, et al. A recombinant Newcastle disease virus (NDV) expressing infectious laryngotracheitis virus (ILTV) surface glycoprotein D protects against highly virulent ILTV and NDV challenges in chickens. Vaccine. 2014;32:3555–3563. 17. Yu Q, Spatz S, Li Y, et al. Newcastle disease virus vectored infectious laryngotracheitis vaccines protect commercial broiler chickens in the presence of maternally derived antibodies. Vaccine. 2017;35:789–795.

VAXXITEK® HVT+IBD+ILT The Power to Protect